Answers are grounded in this paper and cite their sources.
Background: Neurodegenerative diseases are increasingly linked to metabolic dysfunction, such as impaired insulin signaling, mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation. These observations have contributed to the type 3 diabetes hypothesis, which describes AD as a disorder associated with brain insulin resistance. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists have emerged as promising therapeutic candidates because of their metabolic and neuroprotective properties. Objective: To evaluate the neuroprotective potential of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in neurodegenerative diseases. Materials and Methods: A structured narrative review was conducted using PubMed, Scopus, and Web of Science databases. Studies published between 2015 and 2026 investigating incretin-based therapies in neurodegenerative disorders were included, encompassing randomized controlled trials, observational studies, meta-analyses, and mechanistic research. Results: Preclinical studies consistently demonstrated neuroprotective effects of GLP-1RAs through modulation of neuroinflammation, oxidative stress, mitochondrial dysfunction, synaptic plasticity, and neuronal survival pathways. Observational studies suggested an association between incretin-based therapies and reduced dementia risk. Clinical trials in AD and PD have yielded heterogeneous results, with efficacy appearing to depend on disease stage and patient characteristics. Dual GLP-1/GIP receptor agonists showed promising mechanistic potential, although clinical evidence remains limited. Conclusions: Incretin-based therapies represent a promising multi-target strategy for neurodegenerative diseases. Their effects extend beyond glycaemic regulation and may influence multiple pathways involved in neurodegeneration. Further large-scale clinical studies are required to determine their disease-modifying potential and optimal therapeutic use.
No takes yet. Share an insight, caveat, or question.
Tekieli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: